- Research Article
1- 10.1212/wnl.0000000000203765
Dose Selection and Clinical Development of Efgartigimod PH20 Subcutaneous in Patients with Generalized Myasthenia Gravis (P1-5.017)
- Apr 25, 2023
- Neurology
- George Li + 16 more +16
To confirm dose selection and rationale of using the reduction of total immunoglobulin G (IgG) levels as a pharmacodynamic (PD) marker of noninferiority for subcutaneous (SC) efgartigimod PH20 (coformulated with recombinant human hyaluronidase PH20).
Read more